欧美最新另类人妖I国产成人av一区二区三区在线观看I九九热精品视频在线观看I国产精品日韩在线I激情av五月婷婷I日韩精品免费

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Candida glabrata Putative transferase CAF17, mitochondrial (CAF17) CSB-YP753225CZI
CSB-EP753225CZI
CSB-BP753225CZI
CSB-MP753225CZI
CSB-EP753225CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Protein FYV8 (FYV8), partial CSB-YP753226CZI
CSB-EP753226CZI
CSB-BP753226CZI
CSB-MP753226CZI
CSB-EP753226CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata GPN-loop GTPase 3 homolog CAGL0G08294g (CAGL0G08294g) CSB-YP753227CZI
CSB-EP753227CZI
CSB-BP753227CZI
CSB-MP753227CZI
CSB-EP753227CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Pescadillo homolog (NOP7), partial CSB-YP753228CZI
CSB-EP753228CZI
CSB-BP753228CZI
CSB-MP753228CZI
CSB-EP753228CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Altered inheritance of mitochondria protein 37, mitochondrial (AIM37) CSB-YP753229CZI
CSB-EP753229CZI
CSB-BP753229CZI
CSB-MP753229CZI
CSB-EP753229CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Mitochondrial import inner membrane translocase subunit TIM22 (TIM22), partial CSB-YP753230CZI1
CSB-EP753230CZI1
CSB-BP753230CZI1
CSB-MP753230CZI1
CSB-EP753230CZI1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Mitochondrial outer membrane protein CAGL0G03245g (CAGL0G03245g), partial CSB-YP753231CZI1
CSB-EP753231CZI1
CSB-BP753231CZI1
CSB-MP753231CZI1
CSB-EP753231CZI1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata mRNA 3'-end-processing protein YTH1 (YTH1) CSB-YP753232CZI
CSB-EP753232CZI
CSB-BP753232CZI
CSB-MP753232CZI
CSB-EP753232CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata SWR1-complex protein 4 (SWC4), partial CSB-YP753233CZI
CSB-EP753233CZI
CSB-BP753233CZI
CSB-MP753233CZI
CSB-EP753233CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata GPI mannosyltransferase 3 (GPI10), partial CSB-YP753234CZI
CSB-EP753234CZI
CSB-BP753234CZI
CSB-MP753234CZI
CSB-EP753234CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Vacuolar fusion protein MON1 (MON1), partial CSB-YP753235CZI
CSB-EP753235CZI
CSB-BP753235CZI
CSB-MP753235CZI
CSB-EP753235CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata COP9 signalosome complex subunit 9 (CSN9) CSB-YP753236CZI
CSB-EP753236CZI
CSB-BP753236CZI
CSB-MP753236CZI
CSB-EP753236CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata 5-amino-6- (5-phosphoribosylamino)uracil reductase (RIB7) CSB-YP753237CZI
CSB-EP753237CZI
CSB-BP753237CZI
CSB-MP753237CZI
CSB-EP753237CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Protein DML1 (DML1) CSB-YP753238CZI
CSB-EP753238CZI
CSB-BP753238CZI
CSB-MP753238CZI
CSB-EP753238CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata ATP-dependent kinase YFH7 (YFH7) CSB-YP753239CZI
CSB-EP753239CZI
CSB-BP753239CZI
CSB-MP753239CZI
CSB-EP753239CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Small COPII coat GTPase SAR1 (SAR1) CSB-YP753240CZI
CSB-EP753240CZI
CSB-BP753240CZI
CSB-MP753240CZI
CSB-EP753240CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Oxidant-induced cell-cycle arrest protein 5 (OCA5), partial CSB-YP753241CZI
CSB-EP753241CZI
CSB-BP753241CZI
CSB-MP753241CZI
CSB-EP753241CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata rRNA-processing protein CGR1 (CGR1) CSB-YP753242CZI
CSB-EP753242CZI
CSB-BP753242CZI
CSB-MP753242CZI
CSB-EP753242CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Mediator of RNA polymerase II transcription subunit 12 (SRB8), partial CSB-YP753243CZI
CSB-EP753243CZI
CSB-BP753243CZI
CSB-MP753243CZI
CSB-EP753243CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Candida glabrata Assembly factor CBP4 (CBP4), partial CSB-YP753244CZI
CSB-EP753244CZI
CSB-BP753244CZI
CSB-MP753244CZI
CSB-EP753244CZI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.practicalworld.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>



×